Skip to main content

Table 2 Distributions of DPP-4 activity in kidney

From: Protective effects of DPP-4 inhibitor on podocyte injury in glomerular diseases

 

Diagnosis

Podocyte

Bowman’s capsule

Proximal tubule

Distal tubule

Interstitial tissue

others

case 1

Minor glomerular abnormalitya

–

+/−

+

–

–

 

case 2

Minor glomerular abnormality

–

+/−

++

–

–

 

case 3

Minor glomerular abnormality

–

+

++

–

–

 

case 4

ANCA-RNa

–

+

++

–

–

crescent ++

case 5

ANCA-RN

–

+

+

–

–

crescent +

case 6

ANCA-RN with DPP-4i

–

–

+

–

–

 

case 7

ANCA-RN

–

+/−

+

–

–

crescent -

case 8

FSGSa

+

+

++

–

–

 

case 9

FSGS

+

+

++

–

–

 

case 10

FSGS

+

+

++

–

–

 

case 11

FSGS

+/−

+

++

–

–

 

case 12

FSGS

+

+/−

+

–

–

 

case 13

FSGS

+

+/−

++

–

–

 

case 14

FSGS

+

+

++

–

–

 

case 15

Nephrosclerosisa

–

–

++

–

–

 

case 16

DN w/o DPP-4iab

+

+/−

++

–

–

nodule +

case 17

DN w/o DPP-4ib

+

+/−

+

–

–

nodule +

case 18

DN w/o DPP-4ib

+/−

+

++

–

–

nodule +

case 19

DN with DPP-4ib

+/−

+/−

+

–

–

 

case 20

DN with DPP-4i

+

+

++

–

–

 

case 21

DN with DPP-4i

+/−

+/−

+

–

–

 

case 22

DN with DPP-4i

+/−

+/−

+

–

–

 

case 23

DN with DPP-4i

–

–

+

–

–

 

case 24

DN with DPP-4i

+

+/−

+

–

–

 

case 25

DN with DPP-4ib

–

+

–

–

–

 

case 26

DN with DPP-4ib

–

–

+/−

–

–

 

case 27

DN with DPP-4ib

+

+/−

+/−

–

–

nodule +

  1. ANCA-RN ANCA-related nephritis, FSGS focal segmental glomerular sclerosis, DN w/o DPP-4i diabetic nephropathy without DPP-4 inhibitor treatment, DN with DPP-4i diabetic nephropathy treated with DPP-4 inhibitor
  2. DPP-4 activity was evaluated in -, +/−, +, ++
  3. a: indicated in Fig. 1, b: indicated in Fig. 2